386 related articles for article (PubMed ID: 21477075)
1. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Zangari M; Aujay M; Zhan F; Hetherington KL; Berno T; Vij R; Jagannath S; Siegel D; Keith Stewart A; Wang L; Orlowski RZ; Belch A; Jakubowiak A; Somlo G; Trudel S; Bahlis N; Lonial S; Singhal S; Kukreti V; Tricot G
Eur J Haematol; 2011 Jun; 86(6):484-7. PubMed ID: 21477075
[TBL] [Abstract][Full Text] [Related]
2. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Vij R; Siegel DS; Jagannath S; Jakubowiak AJ; Stewart AK; McDonagh K; Bahlis N; Belch A; Kunkel LA; Wear S; Wong AF; Wang M
Br J Haematol; 2012 Sep; 158(6):739-48. PubMed ID: 22845873
[TBL] [Abstract][Full Text] [Related]
3. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Zangari M; Esseltine D; Lee CK; Barlogie B; Elice F; Burns MJ; Kang SH; Yaccoby S; Najarian K; Richardson P; Sonneveld P; Tricot G
Br J Haematol; 2005 Oct; 131(1):71-3. PubMed ID: 16173965
[TBL] [Abstract][Full Text] [Related]
4. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
Steele JM
J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
[TBL] [Abstract][Full Text] [Related]
6. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA; Wong A; Orlowski RZ; Siegel DS
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):310-8. PubMed ID: 23040437
[TBL] [Abstract][Full Text] [Related]
7. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Vij R; Wang M; Kaufman JL; Lonial S; Jakubowiak AJ; Stewart AK; Kukreti V; Jagannath S; McDonagh KT; Alsina M; Bahlis NJ; Reu FJ; Gabrail NY; Belch A; Matous JV; Lee P; Rosen P; Sebag M; Vesole DH; Kunkel LA; Wear SM; Wong AF; Orlowski RZ; Siegel DS
Blood; 2012 Jun; 119(24):5661-70. PubMed ID: 22555973
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
9. Response to bortezomib and activation of osteoblasts in multiple myeloma.
Zangari M; Yaccoby S; Cavallo F; Esseltine D; Tricot G
Clin Lymphoma Myeloma; 2006 Sep; 7(2):109-14. PubMed ID: 17026821
[TBL] [Abstract][Full Text] [Related]
10. [Serum ALP elevation early after treatment is a predictor for response in myeloma patients treated with bortezomib].
Minauchi K; Shima K; Hashiguchi J; Ara T; Yasumoto A; Fujino K; Nakata M; Obara M; Ota S; Imai K; Hirano T; Kiyama Y; Ogasawara M; Kobayashi N; Imamura M
Rinsho Ketsueki; 2015 Aug; 56(8):1064-8. PubMed ID: 26345568
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib: a novel second-generation proteasome inhibitor.
Khan ML; Stewart AK
Future Oncol; 2011 May; 7(5):607-12. PubMed ID: 21568676
[TBL] [Abstract][Full Text] [Related]
12. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib for the treatment of multiple myeloma.
Lue J; Goel S; Mazumder A
Drugs Today (Barc); 2013 Mar; 49(3):171-9. PubMed ID: 23527321
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
16. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
17. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J
Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
Squifflet P; Michiels S; Siegel D; Vij R; Jagannath S; Saad ED; Rajangam K; Ro SK; Buyse M
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):680-6. PubMed ID: 26482107
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
